TRex Bio, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on October 13, 2026, reporting on amendments to its governing documents. The filing indicates that these changes were made in connection with the company's initial public offering (IPO) of common stock.
The company filed a fourth amended and restated certificate of incorporation with the Secretary of State of Delaware, which became effective upon filing. The new charter amends and restates the previous certificate in its entirety. Key provisions include the authorization of 225 million shares of common stock, par value $0.0001 per share. Additionally, the charter authorizes 25 million shares of undesignated preferred stock, par value $0.0001 per share, which may be issued in one or more series with board approval. The filing also notes the elimination of all references to previously existing series of preferred stock and the removal of the ability for stockholders to take action by written consent.
Separately, the company’s second amended and restated bylaws became effective on the same date. These bylaws amend and restate the previous bylaws entirely. Changes include the establishment of procedures for stockholder proposals and director nominations, as well as modifications to indemnification provisions for directors and officers. The bylaws were updated to conform to the new provisions of the Amended and Restated Certificate of Incorporation.
The filing lists the company’s principal executive address as 269 East Grand Avenue, Suite 300, South San Francisco, CA 94080.
